Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Tekturna Side Effect Lawsuits | Lawsuit, Lawyer, Attorney | Side Effects: Kidney Problems, Strokes, Non-fatal stroke, Hyperkalemia (high potassium), Hypotension (low blood pressure), Other Complications

Blood Pressure Drug, Tekturna Linked to Kidney Problems and/or Stroke

Tekturna (Aliskiren) is Used for High Blood Pressure, but it Could Also Lead to Strokes and Kidney Problems

Tekturna (Aliskiren) is Used for High Blood Pressure, but it Could Also Lead to Strokes and Kidney Problems

Tekturna (aliskiren) is a medication manufactured by Novartis that is used to treat high blood pressure, but it might also lead to complications such as a stroke, kidney problems, potentially deadly sensitivity and other side effects. In fact, this drug raised so many safety concerns that a major study had to be stopped because of its related side effects. Tekturna is also sold under the brand name Rasilez in Europe. Other medications that also use aliskiren as the main active ingredient include:

  • Tekturna HCT
  • Valturna
  • TekAmlo
  • Amturnide

Research Study Stopped Because of Tekturna Side Effects

In December 2011, Novartis had to stop a clinical study looking at the effects of Tekturna because experts were worried about the side effects seen in patients who were taking the drug. The study was titled ALTITUDE, and it involved 8,606 patients from 36 different countries. Novartis launched ALTITUDE hoping to show that Tekturna would help reduce the risk of heart and renal complications in patients with Type 2 diabetes and kidney impairment. Instead, an independent review committee found that the patients who took Tekturna in combination with two other types of hypertension drugs (ACE inhibitors and ARBs) had higher rates of the following complications:

  • Non-fatal stroke
  • Renal (kidney) complications
  • Hyperkalemia (high potassium)
  • Hypotension (low blood pressure)
  • Angioedema

The review committee also found that in high risk populations, there was a higher incidence of these side effects after 18-24 months.

Patient Safety Group Warns that Tekturna is Linked to Deadly Swelling

Angioedema is a hypersensitivity reaction that causes rapid swelling, usually in the face, lips, tongue and throat. This condition can also affect the hands and become fatal if the swelling causes the airway to close. According to the Institute for Safe Medication Practices (ISMP), some people taking Tekturna have experienced angioedema. The swelling, which may take several minutes or several hours to appear, is sometimes described as feeling itchy or painful.

Contact Us

At Parker Waichman LLP, we are dedicated to fighting for the rights of people who have been injured by defective drugs. Our firm also offers a free legal consultation for anyone who has questions about Tekturna.

If you or someone you know experienced a stroke, kidney problems, angioedema or other side effect that you think may have come from taking Tekturna, you may have valuable legal rights. To find out more, please fill out our online form or call our office at 1(800)-YOURLAWYER (1-800-968-7529).


TekturnaRSS Feed

Blood Pressure Medication Tekturna Linked to Potentially Deadly Complications, Says Public Safety Group

Nov 1, 2012
Parker Waichman LLP is reporting that Tekturna, a drug used to treat hypertension, is associated with potentially fatal side effects. According to a report by the Institute for Safe Medication Practices (ISMP), the U.S. Food and Drug Administration (FDA) received at least 100 adverse event reports linked to the drug; among them were reports of angioedema, a rapid swelling that can lead to airway obstruction. Parker Waichman, a national law firm dedicated to protecting the...

Novartis Updating Tekturna Label with Warnings for Diabetes, Kidney Patients. Announces Valturna Market Withdrawal.

Apr 20, 2012 | Parker Waichman LLP
Novartis has announced that it will be making changes to the labels for Tekturna and other aliskiren-based medications regarding serious risks posed by such drugs when they are used by diabetics or patients with kidney failure who are also taking ACE Inhibitors or angiotensin receptor blockers (ARBs).  Novartis also said it will pull the drug Valturna, a single pill combination of aliskiren and the ARB valsartan, from the U.S. market by July 20, 2012. According to a statement from...

U.K. Regulator Issues Aliskiren (Rasilez and Tekturna) Update

Mar 9, 2012 | Parker Waichman LLP
U.K.'s health regulator has issued a Drug Safety Update detailing new contraindications for diabetics and kidney patients using the blood pressure drug, aliskiren (marketed as Rasilez and Tekturna).  According to the Medicine and Healthcare Products Regulatory Agency (MHRA), the use of aliskiren in combination ACE inhibitors and Angiotensin II receptor blockers (ARB) is now contraindicated in these patients. The MHRA also stated that the combination of aliskiren with an ACE inhibitor or...

Novartis Agrees to New Rasilez Warnings

Feb 20, 2012 | Parker Waichman LLP
Following the halt of the ALTITUDE trial, Novartis has agreed to comply with a request by European regulators change the label for its blood pressure drug, Rasilez, to include a contraindication against combined use of aliskiren with an ACE inhibitor or an ARB in patients with diabetes and/or patients with moderate to severe renal impairment.   Novartis sells Rasilez in the U.S. under the brand name Tekturna.The European Medicines Agency's (EMA) Committee for Medicinal Products for...

More Tekturna News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo